213 related articles for article (PubMed ID: 22209539)
1. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
Raja FA; Hook JM; Ledermann JA
Cancer Treat Rev; 2012 Oct; 38(6):662-72. PubMed ID: 22209539
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic agents in ovarian cancer: past, present, and future.
Monk BJ; Minion LE; Coleman RL
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
[TBL] [Abstract][Full Text] [Related]
3. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
4. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
5. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
9. Cediranib in ovarian cancer: state of the art and future perspectives.
Ruscito I; Gasparri ML; Marchetti C; De Medici C; Bracchi C; Palaia I; Imboden S; Mueller MD; Papadia A; Muzii L; Panici PB
Tumour Biol; 2016 Mar; 37(3):2833-9. PubMed ID: 26753963
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
12. Targeted agents in ovarian cancer.
Kristedja TS; Morgan RJ; Cristea M
Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
[TBL] [Abstract][Full Text] [Related]
13. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic agents in ovarian cancer: dawn of a new era?
Liu J; Matulonis UA
Curr Oncol Rep; 2011 Dec; 13(6):450-8. PubMed ID: 21993845
[TBL] [Abstract][Full Text] [Related]
17. [Characterization of chosen pro-angiogenic factors and anti-angiogenic therapies in ovarian cancer].
Wiśniewski K; Pawłowska A; Bobiński M; Okła K; Kotarski J; Wertel I
Wiad Lek; 2018; 71(8):1603-1607. PubMed ID: 30684347
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
[TBL] [Abstract][Full Text] [Related]
20. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
